dc.contributor.author | Mohammadian, M | |
dc.contributor.author | Shamsasenjan, K | |
dc.contributor.author | Nezhad, PL | |
dc.contributor.author | Talebi, M | |
dc.contributor.author | Jahedi, M | |
dc.contributor.author | Nickhah, H | |
dc.contributor.author | Minayi, N | |
dc.contributor.author | Movassaghpour, A | |
dc.date.accessioned | 2018-08-26T09:01:21Z | |
dc.date.available | 2018-08-26T09:01:21Z | |
dc.date.issued | 2013 | |
dc.identifier.uri | http://dspace.tbzmed.ac.ir:8080/xmlui/handle/123456789/54997 | |
dc.description.abstract | MSCs are multipotent progenitors which reside in bone marrow. They support hematopoietic stem cells homing, self renewal and differentiation in bone marrow. They can also differentiate into osteoblasts, adipocytes, chondrocytes, myocyates and many other tissues. In vivo, when trauma happens, MSCs operate cell renewal and migrate to the damaged tissues to regenerate that injury. In vitro, MSCs are able to proliferate and differentiate to a variety of cell lineages. This makes them a very hopeful tool for cell-based regenerative therapy for large bone defects, maxillofacial skeletal reconstruction, cardiovascular and spinal cord injury and so many other defects. The most important characteristic that make MSCs an excellent tool for cell replacement is their ability to escape from immune rejection. For therapeutic purposes they usually isolated from human bone marrow or fat and they should proliferate in order to reach an adequate number for implantation. Conventionally DMEM medium supplemented with 10% FBS is used for their expansion, but currently autologous platelet rich products are replaced FBS. Platelet granules contain so many growth factors that can support MSCs proliferation. é 2013 by Tabriz University of Medical Sciences. | |
dc.language.iso | English | |
dc.relation.ispartof | Advanced Pharmaceutical Bulletin | |
dc.subject | 5' nucleotidase | |
dc.subject | activated leukocyte cell adhesion molecule | |
dc.subject | beta1 integrin | |
dc.subject | CD9 antigen | |
dc.subject | common acute lymphoblastic leukemia antigen | |
dc.subject | endoglin | |
dc.subject | fibronectin | |
dc.subject | Flt3 ligand | |
dc.subject | Hermes antigen | |
dc.subject | interleukin 11 | |
dc.subject | interleukin 12 | |
dc.subject | interleukin 14 | |
dc.subject | interleukin 15 | |
dc.subject | interleukin 6 | |
dc.subject | interleukin 7 | |
dc.subject | interleukin 8 | |
dc.subject | laminin | |
dc.subject | microsomal aminopeptidase | |
dc.subject | platelet derived growth factor beta receptor | |
dc.subject | Thy 1 antigen | |
dc.subject | vascular cell adhesion molecule 1 | |
dc.subject | vimentin | |
dc.subject | antigen presentation | |
dc.subject | article | |
dc.subject | autologous hematopoietic stem cell transplantation | |
dc.subject | cardiovascular disease | |
dc.subject | cell differentiation | |
dc.subject | cell expansion | |
dc.subject | cell homing | |
dc.subject | cell regeneration | |
dc.subject | cell renewal | |
dc.subject | clinical effectiveness | |
dc.subject | cytokine release | |
dc.subject | diabetes mellitus | |
dc.subject | G1 phase cell cycle checkpoint | |
dc.subject | human | |
dc.subject | immunomodulation | |
dc.subject | immunopathology | |
dc.subject | in vitro study | |
dc.subject | in vivo study | |
dc.subject | lung disease | |
dc.subject | lymphopoiesis | |
dc.subject | mesenchymal stem cell | |
dc.subject | mesenchymal stem cell transplantation | |
dc.subject | myelopoiesis | |
dc.subject | neurologic disease | |
dc.subject | nonhuman | |
dc.subject | protein expression | |
dc.subject | spinal cord injury | |
dc.subject | stem cell mobilization | |
dc.subject | stem cell niche | |
dc.title | Mesenchymal stem cells: New aspect in cell-based regenerative therapy | |
dc.type | Article | |
dc.citation.volume | 3 | |
dc.citation.issue | 2 | |
dc.citation.spage | 433 | |
dc.citation.epage | 437 | |
dc.citation.index | Scopus | |
dc.identifier.DOI | https://doi.org/10.5681/apb.2013.070 | |